Boehringer's Jardiance now gets CDSCO nod for chronic kidney disease
The Central Drugs Standard Control Organisation of India has approved Jardiance, a 10mg dosage form of empagliflozin, for the treatment of chronic kidney disease (CKD). This approval allows nephrologists and cardiologists to use Jardiance for eligible CKD patients, reducing hospitalizations and addressing unmet medical needs.
Disclaimer : Mytimesnow (MTN) lets you explore worldwide viral news just by analyzing social media trends. Tap read more at source for full news. The inclusion of any links does not necessarily imply any endorsement of the views expressed within them.
